Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.

Pivtoraiko VN, Abrahamson EE, Leurgans SE, DeKosky ST, Mufson EJ, Ikonomovic MD.

Neurobiol Aging. 2015 Jan;36(1):12-9. doi: 10.1016/j.neurobiolaging.2014.06.021.

2.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072.

PMID:
21513747
3.

Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-β load and cognitive decline in Alzheimer's disease.

Morawski M, Schilling S, Kreuzberger M, Waniek A, Jäger C, Koch B, Cynis H, Kehlen A, Arendt T, Hartlage-Rübsamen M, Demuth HU, Roßner S.

J Alzheimers Dis. 2014;39(2):385-400. doi: 10.3233/JAD-131535.

PMID:
24164736
4.

Pyroglutamate-Aβ 3 and 11 colocalize in amyloid plaques in Alzheimer's disease cerebral cortex with pyroglutamate-Aβ 11 forming the central core.

Sullivan CP, Berg EA, Elliott-Bryant R, Fishman JB, McKee AC, Morin PJ, Shia MA, Fine RE.

Neurosci Lett. 2011 Nov 14;505(2):109-12. doi: 10.1016/j.neulet.2011.09.071.

5.

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Wirths O, Bethge T, Marcello A, Harmeier A, Jawhar S, Lucassen PJ, Multhaup G, Brody DL, Esparza T, Ingelsson M, Kalimo H, Lannfelt L, Bayer TA.

J Neural Transm (Vienna). 2010 Jan;117(1):85-96. doi: 10.1007/s00702-009-0314-x.

6.

Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.

Ikonomovic MD, Wecker L, Abrahamson EE, Wuu J, Counts SE, Ginsberg SD, Mufson EJ, Dekosky ST.

Arch Neurol. 2009 May;66(5):646-51. doi: 10.1001/archneurol.2009.46.

7.

Brain amyloid-β oligomers in ageing and Alzheimer's disease.

Lesné SE, Sherman MA, Grant M, Kuskowski M, Schneider JA, Bennett DA, Ashe KH.

Brain. 2013 May;136(Pt 5):1383-98. doi: 10.1093/brain/awt062.

8.

Brain amyloid-beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry.

Portelius E, Lashley T, Westerlund A, Persson R, Fox NC, Blennow K, Revesz T, Zetterberg H.

Neurodegener Dis. 2015;15(1):50-7. doi: 10.1159/000369465.

PMID:
25591542
9.

ELISA measurement of specific non-antigen-bound antibodies to Aβ1-42 monomer and soluble oligomers in sera from Alzheimer's disease, mild cognitively impaired, and noncognitively impaired subjects.

Klaver AC, Coffey MP, Smith LM, Bennett DA, Finke JM, Dang L, Loeffler DA.

J Neuroinflammation. 2011 Aug 9;8:93. doi: 10.1186/1742-2094-8-93.

10.

Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, Beach T, Kurth JH, Rydel RE, Rogers J.

Am J Pathol. 1999 Sep;155(3):853-62.

11.

The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging.

Wang J, Dickson DW, Trojanowski JQ, Lee VM.

Exp Neurol. 1999 Aug;158(2):328-37.

PMID:
10415140
12.

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy.

Dammers C, Gremer L, Neudecker P, Demuth HU, Schwarten M, Willbold D.

PLoS One. 2015 Oct 5;10(10):e0139710. doi: 10.1371/journal.pone.0139710.

13.

Precuneus amyloid burden is associated with reduced cholinergic activity in Alzheimer disease.

Ikonomovic MD, Klunk WE, Abrahamson EE, Wuu J, Mathis CA, Scheff SW, Mufson EJ, DeKosky ST.

Neurology. 2011 Jul 5;77(1):39-47. doi: 10.1212/WNL.0b013e3182231419.

14.

Pyroglutamate-Aβ: role in the natural history of Alzheimer's disease.

Gunn AP, Masters CL, Cherny RA.

Int J Biochem Cell Biol. 2010 Dec;42(12):1915-8. doi: 10.1016/j.biocel.2010.08.015. Review.

PMID:
20833262
15.

Normal cognition in transgenic BRI2-Aβ mice.

Kim J, Chakrabarty P, Hanna A, March A, Dickson DW, Borchelt DR, Golde T, Janus C.

Mol Neurodegener. 2013 May 12;8:15. doi: 10.1186/1750-1326-8-15.

16.

Resilience of precuneus neurotrophic signaling pathways despite amyloid pathology in prodromal Alzheimer's disease.

Perez SE, He B, Nadeem M, Wuu J, Scheff SW, Abrahamson EE, Ikonomovic MD, Mufson EJ.

Biol Psychiatry. 2015 Apr 15;77(8):693-703. doi: 10.1016/j.biopsych.2013.12.016.

17.

Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.

Susanto TA, Pua EP, Zhou J; Alzheimer’s Disease Neuroimaging Initiative..

J Alzheimers Dis. 2015;45(1):253-68. doi: 10.3233/JAD-142451.

PMID:
25524955
18.

Amyloid-β oligomers relate to cognitive decline in Alzheimer's disease.

Jongbloed W, Bruggink KA, Kester MI, Visser PJ, Scheltens P, Blankenstein MA, Verbeek MM, Teunissen CE, Veerhuis R.

J Alzheimers Dis. 2015;45(1):35-43. doi: 10.3233/JAD-142136.

PMID:
25547634
19.

The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.

Wang ZX, Tan L, Liu J, Yu JT.

Mol Neurobiol. 2016 Apr;53(3):1905-24. doi: 10.1007/s12035-015-9143-0. Review.

PMID:
25833098
20.

Longitudinal assessment of neuroimaging and clinical markers in autosomal dominant Alzheimer's disease: a prospective cohort study.

Yau WY, Tudorascu DL, McDade EM, Ikonomovic S, James JA, Minhas D, Mowrey W, Sheu LK, Snitz BE, Weissfeld L, Gianaros PJ, Aizenstein HJ, Price JC, Mathis CA, Lopez OL, Klunk WE.

Lancet Neurol. 2015 Aug;14(8):804-13. doi: 10.1016/S1474-4422(15)00135-0.

Items per page

Supplemental Content

Support Center